New Protocol: Rituximab, Lenalidomide, and Ibrutinib in DLBCL
Study
Open-label, single-center, phase II study
|
Previously untreated non-GCB DLBCL
|
60 patients
|
Rituximab 375 mg/m2 (D1), lenalidomide 25 mg D(1-10), and ibrutinib 560 mg continuously (RLI) after two cycles, 6 cycles RLI + Standart CT
|
Efficacy
ORR after two cycles of RLI: 86.2%
|
CR at end of RLI-chemo: 94.5%
|
2-year-PFS and -OS: 91.3% and 96.6%
|
Safety
Any grade AEs: Nausea (85%), peripheral sensory neuropathy (83%), diarrhea (78%), mucositis (75%)
|
Grade ≥3 AEs neutropenia 53%, thrombocytopenia 47%, anemia 38%
|
Westin J. et al. Smart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma
Reviewed by Hasan Cagri Yildirim, MD on Nov 26, 2022
